research 331 An open label clinical trial of the JAK inhibitor tofacitinib for alopecia areata
Tofacitinib helped over half of the patients with severe hair loss regrow at least 50% of their hair.
Search
for
Sort by
Research
90-120 / 1000+ results 
research Janus Kinase inhibitors in dermatology: a review
JAK inhibitors effectively treat skin conditions and topical forms are safer.
research Treatment of Alopecia Areata with Oral JAK Inhibitor : Focusing on Clinical Outcomes with Baricitinib
Baricitinib is an effective treatment for severe alopecia areata.
research Tumor necrosis factor inhibitors and janus kinase inhibitors in the treatment of cicatricial alopecia: A systematic review
Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.
research JAK Inhibitor Baricitinib in the Treatment of Oral Lichen Planus: A Case Report
Baricitinib may effectively treat oral lichen planus.
research Screening for latent infectious disease in patients with alopecia areata before initiating JAK inhibitors therapy: a single-center real-world retrospective study
Comprehensive screening for infections is crucial before starting JAK inhibitors in alopecia areata patients.
research Alopecia Areata, triggered by psychological stress and successfully treated with a Janus kinase inhibitor. Case report
Stress-related hair loss was reversed with a special medication.
research Small Molecule Inhibitors and Inflammatory Skin Diseases
New drugs targeting the JAK-STAT pathway show promise for treating inflammatory skin diseases.
research 5α-Reductase inhibitor therapy: Should physicians be concerned with persistent diminished libido, erectile dysfunction and depression in a subset of patients?
Some patients may experience lasting sexual dysfunction, depression, and other side effects from 5α-reductase inhibitor therapy.
research Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study
Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.
research Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature
JAK inhibitors show promise for treating skin and hair disorders but need more research on long-term safety and effectiveness.
research Serum levels of interleukin-1 (IL-1α, IL-1β) in patients with alopecia areata
IL-1α levels are higher in alopecia areata patients, suggesting a role in the disease.
research Increased serum interleukin-17A levels correlate with disease severity and poor prognostic factors in patients with alopecia areata
Higher IL-17A levels indicate more severe alopecia areata.
research Stress Inhibits Hair Growth in Mice by Induction of Premature Catagen Development and Deleterious Perifollicular Inflammatory Events via Neuropeptide Substance P-Dependent Pathways
Stress stops hair growth in mice by causing early hair growth phase end and harmful inflammation through a specific nerve-related pathway.
research To evaluate the role of interleukin-6 in alopecia areata
Interleukin-6 may play a role in causing alopecia areata.
research El papel de los inhibidores de JAK en la alopecia areata: revisión de la literatura
JAK inhibitors help treat alopecia areata but have high recurrence after stopping.
research Síndrome PRIDE: una práctica forma de identificar los efectos adversos cutáneos de los inhibidores del EGFR
PRIDE syndrome helps identify skin side effects from EGFR inhibitors like erlotinib.
research Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study
Baricitinib is effective and safe for treating severe alopecia areata.
research Adverse cutaneous reactions to the new second-generation tyrosine kinase inhibitors (dasatinib, nilotinib) in chronic myeloid leukemia
Many patients on new leukemia drugs had mild to moderate skin reactions.
research Cutaneous manifestations associated with immune checkpoint inhibitors
Immune checkpoint inhibitors can cause skin issues but are linked to better cancer outcomes.
research Repigmentation and new growth of hairs after anti–interleukin-17 therapy with secukinumab for psoriasis
A man's gray hair got darker and thicker after using a psoriasis drug.
research P07 Pityriasis amiantacea: a unique presentation of psoriasis associated with tumour necrosis factor-α inhibitor therapy
A woman's rare scalp condition worsened after using a specific arthritis medication, suggesting such medications can sometimes trigger or aggravate psoriasis.
research Tyrosine kinase Inhibitors in Dermatology: A Systemic Review
Tyrosine kinase inhibitors show promise in treating some skin diseases but their definitive role in dermatology is still unclear.
research The Association Between 5α-Reductase Inhibitors and the Presence of Subsequent Dry Eye Disease in Androgenetic Alopecia: A TriNetX Database Study
Using 5α-reductase inhibitors for hair loss may increase the risk of dry eye disease.
research Effects of Solvent System and Storage Condition on Chemical Stability of 5(alpha)-Reductase Inhibitor Compounds in Tectona grandis L.f. Leaf Extracts
Store Tectona grandis leaf extracts in slightly acidic, light-protected conditions for best stability.
research Serum Interleukin 17 in Patients with Pattern Hair Loss
Targeting IL-17 could help treat pattern hair loss.
research 554 Repurposing a clinical antimalarial for the therapeutic induction of lethal ER stress targeting BRAF-kinase inhibitor-resistant malignant melanoma
Mefloquine, an antimalarial drug, is effective in killing melanoma cells resistant to other treatments by causing lethal stress in the cells.
research Update on the use of topical calcineurin inhibitors in cutaneous lupus erythematosus
Topical calcineurin inhibitors, especially 0.1% tacrolimus ointment, are effective and well-tolerated for treating cutaneous lupus erythematosus but require more research for standard treatment guidelines.
research Effects of the anti-androgen finasteride on 5α-reduction of androgens in the presence of progesterone in human gingival fibroblasts: modulatory actions of the alkaline phosphatase inhibitor levamisole
Finasteride reduces testosterone conversion, progesterone lessens this, and levamisole enhances finasteride's effect.
research 711 Small molecule wnt pathway inhibitor (SM04755) as a potential topical psoriasis treatment
SM04755 may be an effective topical treatment for psoriasis.